Performance of 18F-fluoride PET or PET/CT for the detection of bone metastases: A meta-analysis

Clinical Nuclear Medicine

Volumn 40, Issue 2, 2015, Pages 103-110

  Shen, Chen Tian ^a   Qiu, Zhong Ling ^a   Han, Ting Ting ^a   Luo, Quan Yong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

18F FDG PET CT; 18F fluoride PET; bone metastases; bone scintigraphy; meta analysis

Indexed keywords

FLUORINE 18; MEDRONATE TECHNETIUM TC 99M; FLUORIDE; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; POSITRON EMISSION TOMOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW; BONE TUMOR; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; EVALUATION STUDY; FEMALE; MALE; MIDDLE AGED; MULTIMODAL IMAGING; SCINTISCANNING; SECONDARY;

BONE NEOPLASMS; FEMALE; FLUORIDES; FLUORINE RADIOISOTOPES; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84921607503     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000000592     Document Type: Article

References (31)

1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-593
2. Buckwalter JA, Brandser EA. Metastatic disease of the skeleton. Am Fam Physician. 1997;55:1761-1768
3. Blau M, Nagler W, Bender MA. Fluorine-18: a new isotope for bone scanning. J Nucl Med. 1962;3:332-334
4. Grant FD, Fahey FH, Packard AB, et al. Skeletal PET with #sup#18#/sup#F-fluoride: applying new technology to an old tracer. JNucl Med. 2008;49:68-78
5. Tateishi U, Morita S, Taguri M, et al. A meta-Analysis of (18)F-Fluoride positron emission tomography for assessment of metastatic bone tumor. Ann Nucl Med. 2010;24:523-531
6. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155:529-536
7. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ. 2001;323:157-162
8. Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 1999;17:2381-2389
9. Schirrmeister H, Guhlmann A, Elsner K, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus #sup#18#/sup#F PET. J Nucl Med. 1999;40:1623-1629
10. Schirrmeister H, Glatting G, Hetzel J, et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 2001;42:1800-1804
11. Hetzel M, Arslandemir C, König HH, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res. 2003; 18:2206-2214
12. Even-Sapir E, Metser U, Flusser G, et al. Assessment of malignant skeletal disease: initial experience with #sup#18#/sup#F-fluoride PET/CT and comparison between #sup#18#/sup#F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med. 2004;45:272-278
13. Even-Sapir E, Metser U, Mishani E, et al. The detection of bone metastases in patients with high-risk prostate cancer: #Sup#99m#/sup#Tc-MDP Planar bone scintigraphy, single-And multi-field-of-view SPECT, 18F-fluoride PET, and #sup#18#/sup#F-fluoride PET/CT. J Nucl Med. 2006;47:287-297
14. Beheshti M, Vali R, Waldenberger P, et al. Detection of bone metastases in patients with prostate cancer by #sup#18#/sup#F fluorocholine and #sup#18#/sup#F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008;35:1766-1774
15. KrügerS, Buck AK, Mottaghy FM, et al. Detection of bone metastases in patients with lung cancer: #Sup#99m#/sup#Tc-MDP planar bone scintigraphy, #sup#18#/sup#F-fluoride PET or #sup#18#/sup#F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:1807-1812
16. Yen RF, Chen CY, Cheng MF, et al. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients. Nucl Med Commun. 2010;31:637-645
17. Withofs N, Grayet B, Tancredi T, et al. #sup#18#/sup#F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun. 2011;32:168-176
18. Iagaru A, Mittra E, Dick DW, et al. Prospective evaluation of (99m)Tc MDP scin-Tigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases. Mol Imaging Biol. 2012;14:252-259
19. Piccardo A, Altrinetti V, Bacigalupo L, et al. Detection of metastatic bone lesions in breast cancer patients: fused (18)F-fluoride-PET/MDCT has higher accuracy than MDCT. Preliminary experience. Eur J Radiol. 2012;81:2632-2638
20. Bortot DC, Amorim BJ, Oki GC, et al. #sup#18#/sup#F-fluoride PET/CTis highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39:1730-1736
21. Chan SC, Wang HM, Ng SH, et al. Utility of #sup#18#/sup#F-fluoride PET/CT and #sup#18#/sup#F-FDG PET/CTin the detection ofbony metastases inheightened-risk head and neck cancer patients. J Nucl Med. 2012;53:1730-1735
22. Kjölhede H, Ahlgren G, Almquist H, et al. Combined #sup#18#/sup#F-fluorocholine and #sup#18#/sup#F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int. 2012;110:1501-1506
23. Wang XY, Rao LJ, Luo BQ, et al. Diagnostic value of (18)F-labeled NaF positron emission tomography-computed tomography imaging in the detection of bone metastases in patients with lung cancer before treatment. Natl Med J China. 2012;92:2495-2498
24. Mosavi F, Johansson S, Sandberg DT, et al. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am J Roentgenol. 2012;199:1114-1120
25. Damle NA, Bal C, Bandopadhyaya GP, et al. The role of #sup#18#/sup#F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CTand #sup#99m#/sup#Tc-MDP bone scan. Jpn J Radiol. 2013;31:262-269
26. Lee SJ, Lee WW, Kim SE. Bone positron emission tomography with or without CT is more accurate than bone scan for detection of bone metastasis. Korean J Radiol. 2013;14:510-519
27. Chakraborty D, Bhattacharya A, Mete UK, et al. Comparison of #sup#18#/sup#F-fluoride PET/CT and #sup#99m#/sup#Tc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma. Clin Nucl Med. 2013;38:616-621
28. Toegel S, Hoffmann O, Wadsak W, et al. Uptake of bone-seekers is solely associated with mineralization. A study with #sup#99m#/sup#Tc-MDP, #sup#153#/sup#Sm-EDTMP and #sup#18#/sup#F-fluoride on osteoblasts. Eur J Nucl Med Mol Imaging. 2006;33:491-494
29. Mariani G, Bruselli L, Kuwert T, et al.A reviewonthe clinical uses of SPECT/CT. Eur J Nucl Med Mol Imaging. 2010;37:1959-1985
30. Horger M, Eschmann SM, Pfannenberg C, et al. Evaluation of combined transmission and emission tomography for classification of skeletal lesions. AJR Am J Roentgenol. 2004;183:655-661
31. Beheshti M, Vali R, Waldenberger P, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2010;12:98-107